|Awarded On||November 02, 2011|
|Title||Novel targeted biologics, Engineered Toxin Bodies (ETB), as cancer therapeutics|
|Program||Product Development Research|
|Award Mechanism||Company Commercialization|
|Institution/Organization||Molecular Templates, Inc.|
|Principal Investigator/Program Director||Jason Kim|
There are over 65,000 cases of Non-Hodgkin Lymphoma (NHL) diagnosed in the US each year (SEER Cancer Statistics, 2010). The use of chemotherapy in combination with biologics that target the extracellular B-cell marker CD20 has dramatically improved outcomes in NHL. The five-year survival rate for the disease has risen from 31% in 1960 to 69% in 2006 (The Leukemia and Lymphoma Society, 2010).
Despite these advances in treatment, most patients still relapse; NHL is still associated with significant morbidity and mortality. It is estimated that more than 20,000 patients a year will die from the disease in the US alone, making it the eighth and sixth most common cause of cancer death in males an...